Bear, thanks for the great posts.

To your last point if apabetalone is showing a 50% to 70% RRR the only issue would be the statistical power and that was determined in the design of the study i.e. they thought this through pre trial.

My feeling is in support of the hypothesis that if the steering committee is delaying to 175 MACE events they may see positive results but not strong enough to show a reasonable statistical significance based on n=150 but perhaps strong enough results to believe statistical significance can be achieved att 250.

This does make me somewhat nervous. We have not data on 3 point MACE with apabetalone.

Also, a delay to 175 events leaves less negotiating time for a possible deal and may even hint to the potential partner to be very conservative.

Exciting time and great posts from many contributors lately.

GLTA

Toinv